|
(Health-NewsWire.Net, May 26, 2015 ) Dallas, TX -- The report Liver Failure Pipeline Review, H1 2015 provides comprehensive information on the therapeutic development for Liver Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Failure and special features on late-stage and discontinued projects.
Liver failure occurs when large parts of the liver become damaged beyond repair and the liver is no longer able to function. Liver failure is a life-threatening condition that demands urgent medical care. The most common causes of chronic liver failure includes: Hepatitis B, Hepatitis C, Long term alcohol consumption, Cirrhosis, Hemochromatosis, Malnutrition. The causes of acute liver failure includes: Acetaminophen overdose, hepatitis A, B, and C, Ingestion of poisonous wild mushrooms.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Liver Failure Pipeline Review, H1 2015 report include: Alfact Innovation, Conatus Pharmaceuticals Inc., Digna Biotech, S.L., Grifols, S.A., Immune Pharmaceuticals, Ltd., Ventria Bioscience.
Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=375209 . (This is a premium report priced at US$2000 for a single user License.)
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of Liver Failure
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Liver Failure and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Liver Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Liver Failure pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Liver Failure
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Liver Failure pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .
RnR Market Research
Ritesh Tiwari
+18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
